Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRC | Q99895 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | MAOA | P21397 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | HTR1A | P08908 | 4/20 | 0.33 |
| ▸ | DRD3 | P35462 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13038788 | 0.78 | MAOA (0.41) | CA12MAOAMAOBHTR1ADRD3 | |
| SCHEMBL20615145 | 0.74 | CYP3A4 (0.51) | CA12MAOAMAOBCYP1A2CYP3A4 | |
| SCHEMBL14824886 | 0.74 | MAOA (0.35) | MAOAMAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL20858621 | 0.73 | CYP2A6 (0.38) | MAOAMAOBCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2610674 | 0.72 | GABRA1 (0.46) | HTR2AHTR2C | |
| SCHEMBL12658946 | 0.71 | CTRC (0.48) | CTRCHTR1ADRD3HTR2AHTR2C | |
| SCHEMBL24946157 | 0.69 | CTRC (0.37) | CTRC | |
| SCHEMBL12533390 | 0.69 | MAOA (0.33) | MAOAMAOBHTR2AHTR2CHTR2B | |
| SCHEMBL10158521 | 0.69 | CYP3A4 (0.42) | CA12MAOAMAOBCYP1A2CYP3A4 | |
| SCHEMBL10158641 | 0.69 | HTR2A (0.38) | CTRCMAOAMAOBHTR1ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8377960-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8354429-B2 | Inhibitors of human immunodeficiency virus replication | GILEAD SCIENCES, INC. (US) | 2013-01-15 | — | — | US | disclosed |
| EP-2220076-B1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INT (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-7956068-B2 | Inhibitors of human immunodeficiency virus replication | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-07 | — | — | US | disclosed |
| US-20110028464-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2011-02-03 | — | — | US | disclosed |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2009062285-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009062308-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028464-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, RTF1 | CTRC 1128/4885CA12 4881/4885MAOA 3403/4885 |
| US-20100305115-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | CCNY, RTF2, POLR2E | CTRC 1173/4885CA12 4852/4885MAOA 2286/4885 |
| US-20100311735-A1 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | RTF2, REV1, POLR1E | CTRC 3662/4885CA12 4883/4885MAOA 3362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.